Don't want to miss the best from Business Standard?
Monday, December 01, 2025 | 11:33 AM ISTहिंदी में पढें
DRL trims workforce costs by 25% amid Revlimid-linked margin strain
There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales
 "Dr Reddy's Laboratories, DRL downsizing, DRL employee cost cuts, Dr Reddy's Laboratories layoffs, pharma layoffs, DRL Revlimid sales, DRL FY24 report, DRL digital therapeutics, DRL nutraceuticals, DRL employee count, DRL Ebitda margin, Nirmal Bang DR")
premium
Analysts who track DRL pointed out that the pharma major had been undertaking strategic moves to improve operational efficiencies in recent years
Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories (DRL) has embarked on a significant downsizing initiative, aimed at reducing workforce costs by about 25 per cent, sources familiar with the development said.
Multiple individuals with knowledge of the matter told Business Standard that the cost-cutting exercise was already underway.
“The internal directive is to reduce manpower-related expenses by around 25 per cent. Several high-salaried employees across various departments have been asked to resign. They include many earning over ₹1 crore annually,” said one person close to the matter, requesting anonymity. The person also added that people aged 50-55 years had been offered
